Q-omics provides the consensus-scored NUP85 profile across patient tissues and cancer cell-line models. NUP85 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NUP85 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, NUP85 protein abundance shows 37,452 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where NUP85 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUP85 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUP85 survival associations across molecular data types. NUP85 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUP85 RNA expression–survival associations across cancer types. High NUP85 expression shows unfavorable associations in ACC, LIHC, KIRC, UVM, KICH and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NUP85 RNA expression.
This table summarizes NUP85 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NUP85. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUP85 shows higher tumor expression in HNSC, BLCA, COAD, KIRP, KIRC and LIHC. The HNSC box plot shows higher NUP85 RNA expression in tumor versus normal tissue (log2 FC = +1.226, t-test p < 0.001).
This table shows molecular features associated with NUP85 in patient tissues and cancer cell lines. In patient samples, NUP85 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NUP85 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
